Cell Source, Inc. financial data

Symbol
CLCS on OTC
Industry
Pharmaceutical Preparations
Location
57 West 57 Th Street, Suite 400, New York, NY
State of incorporation
NV
Fiscal year end
December 31
Former names
TICKET TO SEE, INC. (to 6/26/2014)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -101 % +0.73%
Return On Equity 30.5 % -21.4%
Return On Assets -2.15K % -20.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.5M shares +13.8%
Common Stock, Shares, Outstanding 43.3M shares +12.4%
Entity Public Float 18M USD -60.7%
Common Stock, Value, Issued 43.3K USD +12.4%
Weighted Average Number of Shares Outstanding, Basic 42.4M shares +11.1%
Weighted Average Number of Shares Outstanding, Diluted 42.4M shares +11.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.94M USD +52.2%
General and Administrative Expense 2.13M USD -21.1%
Operating Income (Loss) -4.17M USD +4.94%
Nonoperating Income (Expense) -1.06M USD +13.2%
Net Income (Loss) Attributable to Parent -5.23M USD +6.73%
Earnings Per Share, Basic -0.16 USD/shares +11.1%
Earnings Per Share, Diluted -0.16 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22K USD +747%
Other Assets, Current 543 USD -84%
Assets 265K USD +6.56%
Accounts Payable, Current 2.04M USD +28.8%
Employee-related Liabilities, Current 9.75K USD 0%
Accrued Liabilities, Current 1.49M USD +35.4%
Liabilities 19.2M USD +18%
Retained Earnings (Accumulated Deficit) -45.8M USD -12.9%
Stockholders' Equity Attributable to Parent -18.9M USD -18.2%
Liabilities and Equity 265K USD +6.56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -174K USD +43.8%
Net Cash Provided by (Used in) Financing Activities 152K USD -31%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 43.3M shares +12.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -22.2K USD +75.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23K USD +790%
Deferred Tax Assets, Valuation Allowance 11.8M USD +14.4%
Deferred Tax Assets, Gross 11.8M USD +14.4%
Deferred Tax Assets, Operating Loss Carryforwards 10M USD +10.2%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 26.9M USD +9.43%
Share-based Payment Arrangement, Expense 289K USD -12.5%
Interest Expense 63.3K USD -54.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%